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Mitochondrial DNAMitochondrial DNA (mtDNA) deletions have been reported to accumulate to high levels in substantia nigra
of older humans, and these mutations are suspected of causing age-related degeneration in this area. We
have compared levels of mtDNA deletions in humans and mice and report here that levels of deletions in the
mouse are very signiﬁcantly lower than in humans. While human mtDNA from substantia nigra contained
more than 5% of deleted molecules, mouse substantia nigra contained less than 0.5%. These results imply that
mtDNA deletions are unlikely to play any signiﬁcant role in of murine substantia nigra aging and further call
for caution in using mouse models in studies of the role of mtDNA deletions in aging and neurodegeneration.
On a more general note, these results support the view that critical targets of the various aging processes
may differ signiﬁcantly between distant species.pko).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial DNA mutations have been long suspected to cause
aging in mammals, though their role remains controversial [1].
Endogenous mitochondrial mutations sustain surprisingly high muta-
tional rates [2], and are capable of efﬁcient intracellular expansion,
which eventually results in defect in oxidative phosphorylation [3] and
potentially make age-related accumulation of these mutations a fair
candidate for a signiﬁcant component of the aging process. Of all
mitochondrial mutations (i.e. point mutations and large rearrange-
ments or deletions), the latter are recently receivingparticular attention
in studies from rodents to humans as potential culprits of the age-
related deterioration of various tissues including muscle [4,5], sub-
stantia nigra [6,7], and kidney [8]. Substantial similarities have been
discovered in the distribution ofmtDNA deletions in human and rodent
muscle ﬁbers [4,5]. This latter observation seems to support a general
presumption that the mouse is a reasonable model system for human
aging from themtDNAperspective. The importance of this presumption
is highlighted by recent work using models of mice with increasedrates of mtDNA deletions and a syndrome reminiscent of premature
aging [9–12] as a model of mammalian aging [13]. It has been argued
though that it is key for validationof thesemodels todeterminewhether
the distribution of deletions among various tissues faithfully represents
the distribution that occurs in normal aging, either in the mouse or in
human [14].We have been interested in this issue sincemany years ago
whenwe failed to see anydeletions in a study of a largenumber of single
cardiomyocytes from old murine hearts (Khrapko, unpublished data).
This contrasted with human cardiomyocytes, of which a substantial
proportion showed clonally expanded deleted mtDNA molecules [15].
In humanheart, however, a low fraction of these deletions in each of the
affected cardiomyocytes makes these deletions poor candidates for a
culprit of the aging process. Much higher overall fractions and cell-by-
cell levels of mtDNA deletions have been discovered in the human
substantia nigra [6,7], a compact midbrain area rich in dopaminergic
pigmented neurons. High deletion levels make this area one of themost
probable candidate tissues where age-related deterioration may be
driven by mtDNA deletions. We therefore decided to explore the
hypothesis that mice are similar to humans with respect to the
accumulation of mtDNA deletions in substantia nigra. To do the
comparison, we isolated substantia nigra tissue from aged murine and
human brains andmeasuredmutant fractions of deletedmtDNA. To our
surprise, our experiments demonstrated that the levels of deletions in
aged murine substantia nigra were much lower that those in aged
humans.
Table 1
Fractions of mtDNA substantia nigra deletions in mice are much lower than in humans.
Note that lower conﬁdence limits of the fraction of deletions in human tissue are at least
ﬁve fold higher than the upper conﬁdence limits for themouse (the numbers to compare
are in bold).
Samples Fraction of deletions 95% Conf. limits
Lower Upper
Human s. nigra 80 years old, norm. 0.04 0.028 0.052
80 years old, PD 0.05 0.035 0.065
Mouse s. nigra 27 months old 0.0007 0.000017 0.0037
34 months old 0.002 0.0004 0.006
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2.1. Tissues and DNA preparation
Substantia nigra has been identiﬁed on human midbrain sections
by position and dark color (neuromelanin). The area containing
pigmented neurons was scraped from the section saturated with
glycerol for better visibility as described elsewhere [16]. In the mouse,
substantia nigra was identiﬁed by its position in the midbrain by
inspecting a large series of frozen sections of the entire mouse brain.
The identity of the area was further conﬁrmed by tyrosine
hydroxylase immunostaining of adjacent sections. The tissue was
homogenized in a minimal volume (about 10 μl) of proteinase K/SDS
buffer (0.1 mg/ml proteinase K, 0.5% SDS, 10 mMEDTA).We used two
80-year-old human brains, one normal and one with Parkinson
disease with typical Lewy body pathology. We also analyzed the
brains from a 34-month-old and a 27-month-old mouse. This very
limited number of samples in this comparative study was justiﬁed
based on the similarity of deletion levels in these diverse human
samples (as far as the disease state is considered) compared to the
huge difference in deletion levels between human and murine
samples, in addition to practical considerations relating to available
samples and the large amount of work involved in analyzing large
mtDNA deletion levels in each sample.
2.2. Single molecule PCR
The tissue homogenates were diluted appropriately for single
molecule PCR (smPCR) as described elsewhere [17], i.e. about 3 orders
of magnitude, to the point where about half of multiple parallel PCR
reactions set up using aliquots of the diluted sample were producing
PCR products and half were not. The appropriate dilution was
determined empirically in pilot experiments. Counting the number
of positive reactions allows an estimate of the concentration of
molecules in the original homogenate and of the fraction of mtDNA
deletions as described below. The primers used for PCR were for
human 13-kb PCR: ﬁrst stage nested PCR: 2999F and 16450R,
20 cycles, second stage: 3204F and 16201R, 30 cycles, and for 6-kb
PCR. For mouse mtDNA PCR (13 kb): ﬁrst stage 2417F and 15833R,
20 cycles, second stage 2496F and 1588R, 30 cycles. LaTaq thermo-
stable DNA polymerase from TaKaRa was used according to
manufacturer's recommendations. Each cycle was 20 sec 94C,
13 min 68C for 13-kb PCR and 6 minutes for 6-kb PCR.
3. Results
3.1. Estimation of fraction of deletions, humans vs. mice
Estimating of the fraction of mtDNA deletions by single molecule
PCR is done by counting the number of molecules corresponding to
thewild typemtDNA (13 kb fragment, encompassing the entiremajor
arch and about half of the minor arch) and the number of shorter PCR
fragments (b11 kb), that correspond to mtDNA molecules harboring
large deletions, as determined by agarose gel separation of the PCR
products. The approach we used however was different for human
and mouse samples. Our preliminary estimates demonstrated that
fractions of deletions in human samples of substantia nigra were
relatively high, so our approach was to count, isolate and sequence
these deletions. In contrast, preliminary estimates in the mouse
revealed that murine samples bear very low levels of deletions, so our
strategy was to make an upper estimate of the deletion levels for the
purpose of a statistically sound and conservative comparison to
human, but we did not aim at isolating and studying these rare and
likely functionally irrelevant deletions. The procedures described
below are designed so that the estimates are conservative for human
samples (i.e. our estimates tend to be underestimates), whereas theestimates for the mouse samples tend to be overestimates. These
biases would result in an overall underestimation of the differences in
deletion levels between humans and mice. Thus, our conclusion that
murine levels are much lower than those in humans is highly reliable
as it is based on a “double conservative” estimate.
DilutionsofDNA isolated fromhumansubstantia nigrahomogenates
were treated with the restriction enzyme SnaBI. This treatment
rendered wild type mtDNA molecules non-ampliﬁable (because SnaBI
cuts in the middle of the PCR amplicon). Thus the only ampliﬁable
molecules remaining are mtDNA deletions, i.e. those of them in which
the deleted part includes the SnaBI site. Our previous studies showed
that essentially all deletions in human substantia nigra remove the
SnaBI restriction site [7]. As expected, almost all single molecule PCR
products represent mtDNA deletions (except for a few wild type
molecules that managed to escape restriction). Deletions were counted
and the resultingnumberswereused in statistical analysis. 30molecules
fromoneof the samplesweremappedand sequenced (data not shown).
Each DNA sample was further subjected to single molecule PCR using a
different set of primers which result in a 6-kb-long PCR fragment that
does not encompass the SnaBI site, so that wild type mtDNA molecules
are readily ampliﬁed, and therefore the number of positive reactions in
the corresponding smPCR represented the number of wild type
molecules in the DNA sample. Comparison of the smPCR counts of the
deletions in the 13-kb PCR to the counts of all molecules in the 6-kb PCR
yielded an underestimate of the fraction of deletions in human samples.
This is because the efﬁciency of ampliﬁcation of shorter PCR fragments is
higher that that of longer ones (see Note on controls for artifacts below
for explanation). The vast majority of mtDNA deletions yield PCR
fragments between 6 and 11 kb, and hence comparison to the more
efﬁciently ampliﬁed reference 6 kb fragment would tend to result in an
underestimate of the fraction of deletions.
The 13-kb and 6-kb experiments described abovewere repeated at
least four times for each sample, with over 100 deletions and 6-kb
single molecule PCR fragments harvested per sample, and concentra-
tions of deleted (13-kb PCR) and wild type (6-kb PCR) mtDNA
molecules were determined. Using these estimates of the concentra-
tions of the wild type and the deleted molecules, we calculated that
the lower estimates of the percentage of mtDNA molecules harboring
large deletions in human substantia nigra homogenates to be 4×10−2
(95% conﬁdence limits: 2.8×10−2 to 5.2×10−2) and 5×10−2
(3.5×10−2 to 6.5×10−2) in the two samples we studied.
Mouse homogenates were used without prior restriction enzyme
digestion and were subjected to PCR at single molecule and higher
concentrations. Initial experiments at single molecule concentrations
yielded no deleted PCR products, indicating very low levels of deletions.
The number of wild type molecules in these experiments was used to
estimate mtDNA concentrations in the samples and then PCR was
performed at higher concentrations, corresponding to about 10 wild
type molecules per well (see Table 1). We have run PCR reactions
equivalent to about 1500ampliﬁedwild type genomes, anddetectedone
deleted molecule, or 7×10−4 (95% conf limits: 0.025–5.6 molecules, or
1.7×10−5 to 3.7×10−3) in the 27 month old mouse and 3 deleted
molecules or 2×10−3 (95% conf limits: 0.62–8.8molecules or 4×10−4 to
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assuming Poisson distribution of the counts of molecules [18]. Thus our
estimates of mutant fractions in the mouse are more than an order of
magnitude lower than those for humans and even the upper 95%
conﬁdence limits for both samples are ﬁve times lower than the lower
conﬁdence limits of human estimates.3.2. Note on controls for artifacts
As in any study of low frequency somatic mutations, this study is
potentially at risk of artifacts. Previously we have argued that single
molecule PCR approach is relatively resistant to PCR-derived artifacts
[17]. Nevertheless, appropriate controls are necessary. Possible artifacts
are artiﬁcially generated deleted PCR fragments that may originate in
the jumping PCR [19,20]. This artifact is particularly difﬁcult to control
for, because artiﬁcial deletions may potentially be induced by DNA
damage, so the use of control DNA is not a sufﬁcient measure. Indeed,
the absence of deletions in a control DNA sample does not guarantee
that the procedure is artifact-free, unless one can demonstrate that the
levels of DNA damage are similar between the sample and the control,
which is not a trivial task. In our system, an efﬁcient internal control is
provided by the distribution of breakpoints. Sequencing of deletion
breakpoints demonstrates that breakpoints as determined by our
approach are tightly constrained by biological boundaries, i.e. the
frequency of 5' deletion breakpoints drops dramatically outside so-
called major arch of the mitochondrial genome. Any deletions with 5'
breakpoints outside this area would have removed the light strand
origin of replication and therefore the resulting molecules presumably
would not be able to efﬁciently propagate themselves in vivo. There is no
rational explanation why artiﬁcial DNA damage-induced breakpoints
would not form outside the major arch. In fact there is a signiﬁcant
pressure on artiﬁcial breakpoints to form beyond the light strand origin
as corresponding deletions will result in shorter PCR products and thus
wouldhave a selective advantage in initiatingPCRampliﬁcationbecause
of DNA damage (discussed below). The absence of breakpoints beyond
light strand origin of replication in our set of deletions is thus a strong
argument against a signiﬁcant generation of artiﬁcial deletions in our
experiments.
Another issue related to artifacts is PCR bias. It is well established
that ampliﬁcation efﬁciency decreases with the fragment length,
which may signiﬁcantly distort quantitative PCR results. This problem
has been circumvented in our experiments by the use of smPCR.
Ampliﬁcation of a single molecule obviously ensures that there is no
competition between molecules of different length as they are
segregated into different PCR reaction tubes [17]. Note that this
problem does not pertain to quasi-smPCR conditions used in this
study: we did run PCR reactions withmultiple wild typemolecules for
the mouse mtDNA. Since in this case our goal was to count shorter
deleted molecules among an excess of wild type molecules, their
better ability to amplify merely made our task easier and in no way
could have distorted our results.
Amore difﬁcult to address source of bias is the variable DNAdamage.
To illustrate this phenomenon let us assume that human DNA is more
damaged that that of the mouse. If a lesion completely prevents a DNA
molecule from PCR ampliﬁcation [21], then a higher incidence of such
lesions in human DNA could result in a higher relative number of
ampliﬁable deleted mtDNA molecules in humans than in the mouse,
because shorter deleted molecules have proportionally a lower
probability of sustaining a PCR impassable lesion. In that case, deleted
mtDNA molecules would have an advantage in single molecule PCR.
Note that this advantage is realized not during all ampliﬁcation cycles,
but rather at the very ﬁrst duplication only. This would have risen the
possibility that the higher proportion of deletions inhumans is simply an
artifactual consequence of the higher DNA damage in human samples.
Our approach of comparing human deletions with a shorter, 6-kbfragment, and mouse deletions with a longer, 13-kb fragment (see
Results section), addresses this problem .
4. Discussion
Our observation that the incidence of mtDNA deletions in murine
substantia nigra is over an order of magnitude lower than that in
humans came as a surprise, as the general expectation was that mouse
aging is similar to human aging. Our ﬁndings clearly imply that this is
not always the case and calls for caution in interpretation of data
obtained inmodel animals onto human case. It is important to study the
levels and distributions of mtDNA mutations before using a particular
model. Interestingly, in some cases, the murine and the human
distribution and dynamics of mtDNA mutations may be very similar,
as documented in most impressive work of the Aiken group for muscle
[4,5]. The message of this study is that this similarity, however, cannot
be, in general, taken for granted. This result is particularly interesting
because the substantia nigra in humans is considered one of the tissue
typesmost affected bymtDNA deletions. We still do not knowwhether
these high levels of deletions are of any relevance to aging and/or
neurodegenerationof substantia nigra neurons in humans [1], butmuch
lower levels of deletions in mice imply that these deletions most likely
are irrelevant for mouse aging. Interestingly, these lower levels of
mitochondrial deletions in the murine substantia nigra appear to
correlate with another nigral aging phenomenon in substantia nigra: in
humans, dopaminergic neurons of the substantia nigra start accumu-
lating neuromelanin, which is thought to be related to high oxidative
stress in these cells. This process starts around20 years of age inhumans
when the substantia nigra noticeably turns dark in color. In contrast to
humans, the mouse substantia nigra does not turn dark even at oldest
ages, and the amount of melanin in murine dopaminergic neurons
appears much lower and requires special staining techniques to be
detected [22]. It is tempting to speculate that the relative slowness of
both processes, i.e. accumulation of neuromelanin and deletions inmice
reﬂect some fundamental difference in the aging of substantia nigra in
humans and mice.
We have previously reported that a majority of pigmented neurons
of the substantia nigra in humans at old age contain over 50% of mtDNA
deletions. This result is fully compatible with our lower current
estimates of deletion levels in human substantia nigra homogenates.
The difference probably results from two factors. First, homogenates
contain many other cells besides pigmented neurons, and we have
demonstrated earlier [7] that most other cell types in the brain contain
much lower levels of deletions. Therefore, the presence of other cells
results in effective “dilution” of deletions. Second, as we argued above,
the estimates in this study are only lower estimates of the true level of
deletions in the human substantia nigra. It should be noted that in our
calculations we assumed that relative dopamine neuronal density is
similar in themouse and humans. If, for example, the relative number of
dopaminergic neurons (compared to other cell types presumably not
carrying mtDNA deletions) in the mouse is lower than in humans, then
higher effective “dilution” of their mitochondrial DNA might be
responsible in part for the apparent lower fraction of deletions in the
mouse. While visually cell densities appear to be similar in mouse and
humans, it would be important to perform a detailed cell-by-cell
investigation in the mouse and compare the results to the same in
humans [7] to fully resolve this issue.
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